| Name | Title | Contact Details |
|---|
Our dedicated attorneys with impressive trial experience and impeccable reputations represent clients nationwide and can help change your life by legalizing your status so you can remain here with your family, for good. Our mission is to bring compassion back to law by protecting client rights, representing and fighting for what our clients deserve. Far too often we see genuine, good people silenced because they dont have the resources they need to see their case through. Nothing can feel more intimidating than sorting through paperwork, keeping track timelines, and navigating the complex immigration system. Our attorneys advocate ruthlessly for your rights with compassionate representation. We anticipate the needs of our clients and are well-versed in proactive planning if you or a loved one are in need immigration support. As our client, you will always be our top priority. That is our promise.
MedVet is the leading veterinarian owned and led network of specialty and emergency hospitals dedicated to delivering exceptional care and a deeply supportive experience to pets and their loving families, referring veterinarians, and team members. For more than 35 years, MedVets empathetic, insightful, and driven team of expert caregivers has helped the organization grow to be the preferred choice for high quality, compassionate care, proudly serving more than 500,000 patients each year in communities throughout the United States. Our caregivers are deeply committed to MedVets mission of Leading Specialty Healthcare for Pets and our driven by our core values of Teamwork, Leadership, and Compassion. Visit www.medvet.com for further information and to view employment opportunities at MedVet. MedVet is an Equal Opportunity Employer.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
The globally operating Geberit Group is a European leader in the field of sanitary products. Geberit operates as an integrated group with a very strong local presence in many countries, providing unique added value in sanitary technology and bathroom ceramics. The Group is headquartered in Rapperswil-Jona, Switzerland, with a production network encompassing more than 30 production facilities. In North America, Geberit provides concealed systems for wall-hung toilets and fixtures. Geberit systems improve the look of any bathroom by hiding unsightly plumbing hardware. Replacing a standard toilet with the Geberit system results in more usable space, improved hygiene, and better accessibility. The unique dual-flush valve saves water and is practically maintenance-free. Geberit also offers cable-controlled bath waste and overflows in a variety of designer finishes. Critical working parts are outside the waterway, ensuring years of trouble-free operation. With more than 12,000 employees in over 40 countries, Geberit generates net sales of CHF 2.6 billion. The Geberit shares are listed on the SIX Swiss Exchange; since 2012, the Geberit share has been included in the SMI (Swiss Market Index).